Product details.

Lameness in 74.7% of horses improved by at least one grade 56 days after treatment. Mild transient colic was only seen following 9.0% of treatments.

Osphos is the only FDA approved intramuscular bisphosphonate injection for the control of the clinical signs associated with navicular syndrome in horses.

With Osphos the benefits are clear . . .

Osphos efficacy.

Clinical improvement in lameness visible 28 days after treatment with Osphos in 67.4% of horses1.

Lameness in 74.7% of horses improved by at least one AAEP grade at 56 days after treatment.

Horses with navicular syndrome positively respond to treatment with Osphos.

1 Internal report Osphos01 (2014)

Product summary.

As with all drugs, side effects may occur. In field studies, the most common side effects reported were signs of discomfort or nervousness, colic, and/or pawing.

Osphos should not be used in pregnant or lactating mares, or mares intended for breeding.

Use of Osphos in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not recommended. Refer to the prescribing information for complete details or visit www.dechra.com.

Caution: Federal Law (USA) restrictions this drug to use by or on the order of a licensed veterinarian.